Targets › SLC13A5
1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Dec 2030.
High-affinity sodium/citrate cotransporter that mediates the entry of citrate into cells, which is a critical participant of biochemical pathways. May function in various metabolic processes in which citrate has a critical role such as energy production (Krebs cycle), fatty acid synthesis, cholesterol synthesis, glycolysis, and gluconeogenesis. (UniProt, Q86YT5)
Open in Phaseline: the race on SLC13A5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| TESS Research Foundation | TSHA-105 AAV9-mediated gene therapy delivering SLC13A5 | SLC13A5 | Phase 1 | SLC13A5 Citrate Transporter Disorder | Dec 2030 |
SLC13A5 Citrate Transporter Disorder (1)
small molecule (1)
TESS Research Foundation (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.